Janjigian, Yelena

Publications

Sort by

Co-Author Network

selected publications

Unique Considerations for Females Undergoing Esophagectomy. Annals of surgery. 2020 Academic Article GET IT
Times cited: 16
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. The Lancet. Oncology. 2020 Academic Article GET IT
Times cited: 262
Paradigms for Precision Medicine in Epichaperome Cancer Therapy. Cancer cell. 2019 Academic Article GET IT
Times cited: 44
Incidence and Risk Factors for Isolated Esophageal Cancer Recurrence to the Brain. The Annals of thoracic surgery. 2019 Academic Article GET IT
Times cited: 20
Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer. The oncologist. 2019 Academic Article GET IT
Times cited: 11
Comment on "Microsatellite Instability as a Predictive Biomarker for Adjuvant Chemotherapy in Gastric Cancer": Are we There Yet?. Annals of surgery. 2019 Article GET IT
Times cited: 2
Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2019 Academic Article GET IT
Times cited: 27
Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 13
EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer discovery. 2018 Academic Article GET IT
Times cited: 122
Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 405
Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2018 Academic Article GET IT
Times cited: 14
Checkpoint blockade in esophagogastric cancer. Journal of surgical oncology. 2018 Information Resource GET IT
Times cited: 8
YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proceedings of the National Academy of Sciences of the United States of America. 2018 Academic Article GET IT
Times cited: 42
Talking to patients about biosimilars. Future oncology (London, England). 2018 Information Resource GET IT
Times cited: 9
Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. Annals of surgical oncology. 2018 Academic Article GET IT
Times cited: 20
Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence?. Clinical colorectal cancer. 2018 Academic Article GET IT
Times cited: 13
Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center: Postsurgical Outcomes in 41 Patients. Annals of surgery. 2017 Academic Article GET IT
Times cited: 33
Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer discovery. 2017 Academic Article GET IT
Times cited: 285
Oncologist use and perception of large panel next-generation tumor sequencing. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 32
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. Lung cancer (Amsterdam, Netherlands). 2017 Academic Article GET IT
Times cited: 11
Pharmacokinetics, Biodistribution, and Radiation Dosimetry for ⁸⁹Zr-Trastuzumab in Patients with Esophagogastric Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017 Academic Article GET IT
Times cited: 98
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature medicine. 2017 Academic Article GET IT
Times cited: 2338
Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. Oncoimmunology. 2017 Academic Article GET IT
Times cited: 68
⁸⁹Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017 Academic Article GET IT
Times cited: 32
Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer. Surgical oncology clinics of North America. 2017 Information Resource GET IT
Times cited: 3
Integrated genomic characterization of oesophageal carcinoma. Nature. 2017 Academic Article GET IT
Times cited: 1253
Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay. The Journal of molecular diagnostics : JMD. 2016 Academic Article GET IT
Times cited: 94
Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma. Journal of gastrointestinal oncology. 2016 Academic Article GET IT
Times cited: 10
It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Article GET IT
Times cited: 19
The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond. Journal of gastrointestinal oncology. 2016 Information Resource GET IT
Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience. Journal of gastrointestinal oncology. 2016 Academic Article GET IT
Times cited: 16
Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma. Cancer. 2016 Academic Article GET IT
Times cited: 28
Risk factors for recurrence in T1-2N0 gastric cancer in the United States and China. Journal of surgical oncology. 2016 Academic Article GET IT
Times cited: 23
Clinical impact of tumour biology in the management of gastroesophageal cancer. Nature reviews. Clinical oncology. 2016 Information Resource GET IT
Times cited: 123
Current advances in targeted therapies for metastatic gastric cancer: improving patient care. Future oncology (London, England). 2016 Information Resource GET IT
Times cited: 3
PKLR promotes colorectal cancer liver colonization through induction of glutathione synthesis. The Journal of clinical investigation. 2016 Academic Article GET IT
Times cited: 60
Lapatinib in Gastric Cancer: What Is the LOGiCal Next Step?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Editorial Article GET IT
Times cited: 10
Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma. British journal of cancer. 2015 Academic Article GET IT
Times cited: 16
Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 112
Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. PloS one. 2015 Academic Article GET IT
Times cited: 41
Morbidity after Total Gastrectomy: Analysis of 238 Patients. Journal of the American College of Surgeons. 2015 Academic Article GET IT
Times cited: 66
Esophageal reinforcement with an extracellular scaffold during total gastrectomy for gastric cancer. Annals of surgical oncology. 2014 Academic Article GET IT
Times cited: 16
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer discovery. 2014 Academic Article GET IT
Times cited: 341
Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014 Academic Article GET IT
Times cited: 4796
CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 171
Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer. American journal of clinical oncology. 2014 Academic Article GET IT
Times cited: 7
Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. Expert opinion on investigational drugs. 2014 Information Resource GET IT
Times cited: 139
Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers. Annals of surgical oncology. 2013 Academic Article GET IT
Times cited: 19
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast cancer research : BCR. 2013 Academic Article GET IT
Times cited: 83
Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus. 2013 Academic Article GET IT
Times cited: 7
Distinguishing benign and life-threatening pneumatosis intestinalis in patients with cancer by CT imaging features. AJR. American journal of roentgenology. 2013 Academic Article GET IT
Times cited: 53
A randomized controlled trial of a cardiopulmonary resuscitation video in advance care planning for progressive pancreas and hepatobiliary cancer patients. Journal of palliative medicine. 2013 Academic Article GET IT
Times cited: 75
Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2013 Academic Article GET IT
Times cited: 90
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012 Academic Article GET IT
Times cited: 128
Genomic dysregulation in gastric tumors. Journal of surgical oncology. 2012 Information Resource GET IT
Times cited: 24
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer discovery. 2012 Academic Article GET IT
Times cited: 613
Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Academic Article GET IT
Times cited: 218
Tobacco use is associated with increased recurrence and death from gastric cancer. Annals of surgical oncology. 2012 Academic Article GET IT
Times cited: 34
A case of advanced gastric cancer. 2012 GET IT
Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Archives of pathology & laboratory medicine. 2011 Academic Article GET IT
Times cited: 54
An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. The oncologist. 2011 Academic Article GET IT
Times cited: 220
Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 58
Molecular classification of gastric cancer: a new paradigm. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 271
MET expression and amplification in patients with localized gastric cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2011 Academic Article GET IT
Times cited: 140
Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Academic Article GET IT
Times cited: 114
Molecularly targeted therapies in advanced gastric cancer. Minerva gastroenterologica e dietologica. 2011 Information Resource GET IT
Times cited: 10
Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 111
Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. Journal of neuro-oncology. 2010 Academic Article GET IT
Times cited: 91
Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. Cancer. 2010 Academic Article GET IT
Times cited: 109
A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. Cancer chemotherapy and pharmacology. 2009 Academic Article GET IT
Times cited: 51
Do molecular diagnostics add to clinical characteristics in selecting patients for gefitinib treatment?. Nature clinical practice. Oncology. 2007 Article GET IT
A role for Wnt signaling in adult T-cell leukemia?. Leukemia research. 2005 Editorial Article GET IT
Eicosanoids produced during interactions between Pseudomonas aeruginosa and alveolar macrophages are species-dependent. Immunology and cell biology. 1989 Academic Article GET IT
Times cited: 5

more ...

less ...

Background

education and training

M.D., New York University School of Medicine 2003
B.S., University of California, San Diego 1998

Contact

full name

Yelena Janjigian

VIVO Weill Cornell Medical College

Yelena Janjigian Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name